Lightnews — Scholar-powered news

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 30

🔥Oncology HERE & NOW Webcast/Podcast🆙
🚨 @realbowtiedoc.bsky.social & @crisbergerot.bsky.social
🎯 #SupportiveCare , the future of #Telemedicine
✅Japanese🇯🇵captions are available in #Youtube
youtu.be/4WYdTostU7w?...
@oncoalert.bsky.social
buzzsprout.com/1324033/epis...

1 4 6

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 29

⏰NOW OUT‼️#ELCC25
🔥COCOON🦋: Preventing Moderate to Severe Dermatologic Adverse Events in 1st-line EGFR-mutant Advanced NSCLC Treated with Amivantamab + Lazertinib
🎙️ Dr. Nicolas Girard
🎯AEs ≥G2: OR 0.19 (95%CI, 0.09–0.40)
✅NCT06120140
#LCSM
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social

2 9

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 26

⏰NOW OUT‼️ #ELCC25
🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS
🎙️Prof. James Yang
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎯Seems like extending the OS for 1️⃣2️⃣ months
✅NCT04487080
#LCSM #EGFR
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social

3 10

Reposted by Hidehito HORINOUCHI

Vun-Sin Lim, PhD @vslim.bsky.social · Mar 23

In January 2025, we joined Taiwan Association for the Study of Lung Cancer (TASLC) in running a reviewer workshop in Taipei. 20 selected participants from Taiwan, Malaysia, Thailand, South Korea & Japan attended the workshop. Thanks TASLC for organizing and support! @jtoonline.bsky.social

1 1 1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @nature.com 🆙
✅Immune evasion through mitochondrial transfer in the tumour microenvironment
🎯Previously unknown mechanism of cancer immune evasion through mitochondrial transfer
👥 Dr. Hideki Ikeda
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...

Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature

Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.

www.nature.com

1 2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @cellpress.bsky.social 🆙
✅Extracellular vesicles (EV) from the lung pro-thrombotic niche drive cancer-associated thrombosis and mets via integrin β2
🎯Lung interstitial macrophages produce Integrin β2 small EVs
👥Dr. Serena Lucotti
#LCSM @oncoalert.bsky.social
www.cell.com/cell/fulltex...

Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2

Cancer-associated thrombosis is a leading cause of mortality. Lucotti et al. uncover the formation of a pro-thrombotic niche in the non-metastatic lung microenvironment that promotes thrombosis and me...

www.cell.com

1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...

2 4

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @cp-cancercell.bsky.social 🆙
✅Turning the kaleidoscope: Innovations shaping the future of clinical trial design
🎯Reshaped, prismatic vision of clinical trials combining different knowledge
👥Dr. Grégoire Marret @lilliansiu.bsky.social
@oncoalert.bsky.social
www.cell.com/cancer-cell/...

Turning the kaleidoscope: Innovations shaping the future of clinical trial design

Current clinical trials are based on rigid designs and drug-centric approaches that can stifle flexibility and innovation. With advances in molecular biology and technology, there is an urgent call to...

www.cell.com

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @natrevclinoncol.bsky.social 🆙
✅Utilizing ctDNA to discover mechanisms of resistance to targeted Tx in pts with mNSCLC
👥Dr. Sophie M. Ernst @drsanjaypopat.bsky.social @benjaminbessemd.bsky.social @christianrolfo.bsky.social
#LCSM @oncoalert.bsky.social #LiquidBiopsy
www.nature.com/articles/s41...

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials - Nature Reviews Clinical Oncology

Acquired resistance is a common occurrence among patients with oncogene-driven non-small-cell lung cancer receiving targeted therapies. Monitoring of circulating tumour DNA in liquid biopsy samples pr...

www.nature.com

1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @cp-cancercell.bsky.social 🆙
✅Distinct CD8+ T cell dynamics associate with response to neoadj cancer immunotherapies
🎯Doublet regimen-specific transcriptional and clonal dynamics of tumor-reactive CD8+ T cells
👥Dr. Housaiyin Li
@oncoalert.bsky.social
www.cell.com/cancer-cell/...

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies

Li et al. analyze CD8+ T cells collected from HNSCC patients treated with neoadjuvant immunotherapies. They show that different combination immunotherapies modulate CD8+ T cell functional states throu...

www.cell.com

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 Annals of Oncology @myesmo.bsky.social 🆙
✅Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology
🎯Balanced, patient-oriented trial designs are eagerly warranted
👥Dr. Gabriele Antonarelli
#LCSM @oncoalert.bsky.social
www.annalsofoncology.org/article/S092...

Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology

Randomized clinical trials represent the gold standard for the introduction of innovative therapies in medical oncology, and they provide the highest level of evidence to ascertain the clinical activi...

www.annalsofoncology.org

2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @natmedicine.bsky.social 🆙
✅A B7H3-targeting antibody–drug conjugate (YL201) in advanced solid tumors: a phase 1/1b trial
🎯ORR ES-SCLC 63.9%, lung adenocarcinoma 28.6%, and lymphoepithelioma-like carcinoma 54.2%
👥Dr. Yuxiang Ma
#LCSM @oncoalert.bsky.social #ADC
www.nature.com/articles/s41...

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial - Nature Medicine

In a large-scale, international, multicenter, phase 1/1b trial, treatment of patients with advanced solid tumors with the B7H3-targeting antibody–drug conjugate YL201 was safe and showed preliminary c...

www.nature.com

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @jtoonline.bsky.social 🆙
✅CROWN👑5y: First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC
🎯HR 0.22 (95%CI: 0.13‒0.37), 5-year PFS was 63% (95% CI: 49–74) by lorlatinib
👥 Prof. Yi-long Wu
#LCSM @oncoalert.bsky.social
jto.org/article/S155...

First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patie...

jto.org

1 2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 Journal of Clinical Oncology @ascocancer.bsky.social 🆙
✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer
🎯mOS 47.6 (pretreated pts), not reached (Tx-naïve)
👥 Dr. OliverGautschi
#LCSM @oncoalert.bsky.social @ascopost.bsky.social
ascopubs.org/doi/10.1200/...

Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial

LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up...

ascopubs.org

2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🌟 @iaslc.bsky.social @jtoonline.bsky.social
🔥Recipients of TOP5️⃣REVIEWERS
1️⃣Dr. Paolo Bironzo
2️⃣Dr. Nicolas Girard
3️⃣Dr. William Evans
4️⃣ @hhorinouchi.bsky.social
5️⃣Dr. Voon Pei Jye
🎉Congratulations🎊
#LCSM @oncoalert.bsky.social

IASLC @iaslc.bsky.social · Mar 17

🏅 Cheers to the Top 5 Reviewers for #JTOCRR in 2024! 🏅 Your hard work drives lung cancer research.

👏Thank you to Paolo Bironzo, Nicolas Girard, William Evans, Hidehito Horinouchi, & Pei Jye Voon for your contributions to JTO CRR! 👏

🔹 Apply for the 2025 Reviewer Workshop: bit.ly/ReviewerWS

1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 International Journal of Clinical Oncology 🆙
✅Japan Society of Clinical Oncology position paper
🩸Molecular residual disease #MRD
👥 @Shin Kobayashi
😃Huge thanks to Drs. Takayuki Yoshino and Yoshiaki Nakamura, and great team.
@oncoalert.bsky.social #Liquidbiopsy
link.springer.com/article/10.1...

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing - International Journal of Clinical Oncology

Although the 5-year relative survival rates for resectable solid tumors have improved over the past few years, the risk of postoperative recurrence necessitates effective monitoring strategies. Recent...

link.springer.com

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🌟 #DiaryofanOncologyLeader
🎙️ @solangepeters.bsky.social
🎤Interviewer @drjnaidoo.bsky.social
☑️Maxims for Oncologists
1️⃣Find your sponsors
2️⃣Don't worry about negative feedbacks
3️⃣ Free from guiltiness
4️⃣Overcome imposter syndrome
@oncoalert.bsky.social
youtube.com/watch?v=i6fe...

Diary of an oncology leader: Episode 1 – Solange Peters

YouTube video by European Society for Medical Oncology (ESMO)

youtube.com

1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @naturecancer.bsky.social 🆙
✅Hallmarks of artificial intelligence contributions to precision oncology
🎯Cancer prevention and diagnosis
🎯Optimizing current treatments
🎯Advancing new treatments by
👥Dr. Tian-Gen Chang
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s43...

Hallmarks of artificial intelligence contributions to precision oncology - Nature Cancer

Ruppin and colleagues overview recent research on the use of AI frameworks in precision oncology, describe ten hallmarks of their contributions across cancer detection, therapy optimization and treatm...

www.nature.com

2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @natrevcancer.bsky.social 🆙
✅ALK in cancer: from function to therapeutic targeting
🎯Multipronged approach directed against pathways that sustain the persistence of ALK+ tumors
👥Dr. Claudia Voena
#LCSM @oncoalert.bsky.social @alkpositive.bsky.social
www.nature.com/articles/s41...

ALK in cancer: from function to therapeutic targeting - Nature Reviews Cancer

ALK genetic alterations drive various malignancies through aberrant tyrosine kinase activation, promoting oncogenic cell growth and survival. Here, Voena et al. outline recent advances in ALK oncogeni...

www.nature.com

1 2

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 Annals of Oncology @myesmo.bsky.social 🆙
✅Efficacy assessment in phase I clinical trials: endpoints and challenges
🎯Multiple efficacy endpoints, beyond classic endpoints, have been proposed for efficacy assessment
👥Dr. M.A. Gouda
@oncoalert.bsky.social
www.annalsofoncology.org/article/S092...

Efficacy assessment in phase I clinical trials: endpoints and challenges

The scope of phase I clinical trials in oncology goes beyond the conventional safety evaluation–only objectives of these trials in other specialties. Rather, most first-in-human cancer trials have the...

www.annalsofoncology.org

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @naturerevdrugdisc.bsky.social 🆙
✅Tumour-agnostic kinase inhibitors
🎯Precision medicine paradigm that has successfully launched tumour-agnostic drug development
👥Drs. Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
@oncoalert.bsky.social
www.nature.com/articles/s41...

Tumour-agnostic kinase inhibitors - Nature Reviews Drug Discovery

Multiple tumour-agnostic kinase inhibitors have been approved that are clinically effective regardless of tumour location. This Review describes the origins of tumour-agnostic drug development, focusi...

www.nature.com

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 Lung Cancer @myesmo.bsky.social 🆙
✅A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent NSCLC
🎯ORR 21% in PTK7-expressing, NSQ, EGFR wild NSCLC
👥 Prof. Byoung Chul Cho
✅NCT04189614
#LCSM @oncoalert.bsky.social
www.lungcancerjournal.info/article/S016...

A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer

Lung cancer is the second most common form of cancer and the leading cause of cancer-related deaths worldwide, with global estimates at 2.2 million new diagnoses and 1.8 million deaths annually [1,2]....

www.lungcancerjournal.info

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @iaslc.bsky.social @jtoonline.bsky.social 🆙
🥰TOP10 reviewers for 2024
Dr. Jordi Remon
Dr. Dipesh Uprety
Dr. Molly Siu Ching Li
Dr. Kuan-Yu Chen
Dr. Junko Tanizaki
Dr. Tomer Meirson
Dr. Stephanie Saw
@hhorinouchi.bsky.social
Dr. Misako Nagasaka
Dr. Jean-Louis Pujol
#LCSM
jto.org/article/S155...

1 1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @jtoonline.bsky.social 🆙
✅JCOG2007 (NIPPON): Gut Microbiota in Advanced NSCLC Receiving Chemo-ICI
🎯Differences in microbial diversity and specific bacterial genera were associated with prognosis and serious AEs
👥 Dr. Taiki Hakozaki
#LCSM @oncoalert.bsky.social
jto.org/article/S155...

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)

Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker,...

jto.org

1 1

Hidehito HORINOUCHI @hhorinouchi.bsky.social · Mar 22

🔥 @thelancet.bsky.social 🆙
✅HARMONi-2: Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer
🎯PD-L1 ≥1% HR 0.51 [95% CI 0.38–0.69], PD-L1 ≥50% HR 0.48 [0.29–0.79]
👥Dr. Anwen Xiong
#LCSM @oncoalert.bsky.social
thelancet.com/journals/lan...

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Ivonescimab significantly improved PFS compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer. Therefore, ivonescimab might represent anot...

thelancet.com

1